NCT02168686View on ClinicalTrials.gov

Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 28, 2017

Primary Completion Date

August 29, 2019

Study Completion Date

August 29, 2019

Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
GENETIC

ADVM-043

Gene transfer vector administration

Trial Locations (2)

29425

Medical University of South Carolina, Charleston

32610

University of Florida, Gainesville

Sponsors
All Listed Sponsors
lead

Adverum Biotechnologies, Inc.

INDUSTRY